ExpreS2ion Biotech Holding AB Market Cap ($1.06 Million)
Market Cap & Net Worth: ExpreS2ion Biotech Holding AB (EXPRS2)
ExpreS2ion Biotech Holding AB market cap. ExpreS2ion Biotech Holding AB (ST:EXPRS2) has a market capitalization of $1.06 Million (Skr9.88 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30632 globally and #706 in its home market, demonstrating a 1.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ExpreS2ion Biotech Holding AB's stock price Skr1.00 by its total outstanding shares 9883280 (9.88 Million). Also see EXPRS2 operating cash flow for how efficiently the company converts equity into cash flow.
ExpreS2ion Biotech Holding AB Market Cap History (2016–2026)
ExpreS2ion Biotech Holding AB market cap history from 2016 to 2026. Data shows change from $213.47 Million to $1.06 Million (-38.65% CAGR). Check today's stock price for ExpreS2ion Biotech Holding AB for real-time trading data and today's change.
Index Memberships
ExpreS2ion Biotech Holding AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.01% | #235 of 281 |
Weight: ExpreS2ion Biotech Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ExpreS2ion Biotech Holding AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ExpreS2ion Biotech Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore EXPRS2 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.62x
ExpreS2ion Biotech Holding AB's market cap is 4.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $213.47 Million | $4.65 Million | -$8.54 Million | 45.89x | N/A |
| 2017 | $307.35 Million | $9.79 Million | -$9.84 Million | 31.38x | N/A |
| 2018 | $188.51 Million | $8.87 Million | -$16.82 Million | 21.26x | N/A |
| 2019 | $115.00 Million | $13.83 Million | -$16.70 Million | 8.32x | N/A |
| 2020 | $349.10 Million | $5.26 Million | -$31.71 Million | 66.38x | N/A |
| 2021 | $1.18 Billion | $12.23 Million | -$43.92 Million | 96.23x | N/A |
| 2022 | $558.90 Million | $5.09 Million | -$118.61 Million | 109.89x | N/A |
| 2023 | $76.71 Million | $7.05 Million | -$91.40 Million | 10.88x | N/A |
| 2024 | $21.91 Million | $3.01 Million | -$36.04 Million | 7.27x | N/A |
| 2025 | $16.91 Million | $3.66 Million | -$38.09 Million | 4.62x | N/A |
Competitor Companies of EXPRS2 by Market Capitalization
Companies near ExpreS2ion Biotech Holding AB in the global market cap rankings as of November 5, 2026. Also see EXPRS2 total assets for a full breakdown of the balance sheet.
Key companies related to ExpreS2ion Biotech Holding AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ExpreS2ion Biotech Holding AB (2016–2026)
Market capitalization of ExpreS2ion Biotech Holding AB from 2016 to today. Between 2016 and today, ExpreS2ion Biotech Holding AB's market cap moved from $213.47 Million to $ 1.06 Million, with a yearly change of -38.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.06 Million | -93.71% |
| 2025 | Skr16.91 Million | -22.82% |
| 2024 | Skr21.91 Million | -71.44% |
| 2023 | Skr76.71 Million | -86.27% |
| 2022 | Skr558.90 Million | -52.53% |
| 2021 | Skr1.18 Billion | +237.25% |
| 2020 | Skr349.10 Million | +203.57% |
| 2019 | Skr115.00 Million | -38.99% |
| 2018 | Skr188.51 Million | -38.67% |
| 2017 | Skr307.35 Million | +43.98% |
| 2016 | Skr213.47 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of ExpreS2ion Biotech Holding AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.06 Million USD |
| MoneyControl | $1.06 Million USD |
| MarketWatch | $1.06 Million USD |
| marketcap.company | $1.06 Million USD |
| Reuters | $1.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more